|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN THE EFFECTIVE BENEFICIARIES OF THE SHARES Filed under Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
|||||||||||||||||||||||||
|
Table II – Beneficial ownership derivative securities (for exampleputs, calls, warrants, options, convertible securities)
(for exampleputs, calls, warrants, options, convertible securities)
|
1. Title of derivative title |
2. Conversion or exercise price of the derivative security |
3. Transaction date (month/day/year) |
3A. Deemed execution date, if applicable (month/day/year) |
4. Transaction code |
5. Number of derivative securities acquired (A) or sold (D) |
6. Exercise date and expiry date |
7. Title and amount of the securities underlying the derivative securities |
8. Price of derivative securities |
9. Number of derivative securities beneficially owned as a result of reported transactions |
10. Form of ownership of derivative securities: direct (D) or indirect (I) |
11. Nature of Indirect Beneficial Ownership |
|
Coded |
V |
(A) |
(D) |
Exercise date |
Expiration date |
Title |
Amount or number of shares |
Reporting owners
| Name/address of declaring owner | Relationships | |||
|
Director |
10% Owner |
Officer |
Other |
|
|
CHRISTOPHER J READING |
X |
Chief Executive Officer |
Signatures
|
Christophe J Reading |
2022-03-15 |
| **Signature of declaring person |
Dated |
Explanation of answers:
|
If the form is completed by several declarants, to see |
|
| Section 5(b)(v). |
(**) Intentional misrepresentation or omission of facts are federal criminal offenses. To see |
| 18 USC 1001 and 15 USC 78ff(a). |
(1) |
| The 20,000 common shares were granted as restricted stock pursuant to the Company’s Amended and Restated 2003 Stock Incentive Plan. The restrictions expire in 16 equal quarterly installments with the first 1,250 shares on April 1, 2022 and the last 1,250 shares expiring on January 1, 2026, if employed by the Company on those dates. |
(2) |
Includes the 20,000 shares in footnote 1 and includes 20,711 shares whose restrictions expire at 2,876 on April 1, July 1 and October 1, 2022; 2,879 shares as of January 1, 2023; 1,598 shares on each of April 1, July 1 and October 1, 2023; 1,610 shares as of January 1, 2024; and 700 shares on each of April 1, July 1 and October 1, 2023 and January 1, 2025, if he is an employee of the Company on these dates. Note: Submit three copies of this form, one of which must be manually signed. If space is insufficient, To see
Instruction 6 for the procedure. Potential individuals who need to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Warning USPh – US Physiotherapy Inc. published this content on March 15, 2022 and is solely responsible for the information contained therein. Distributed bypublic unedited and unmodified, onMarch 15, 2022 14:01:04 UTC
.
|
|
|
|
|
|
Analyst Recommendations for US PHYSICAL THERAPY, INC.
|
|
–
|
|
||||
|
||||
US Physical Therapy, Inc. Technical Analysis Chart | MarketScreener
| Short term | Middle term | ||
| Long term | Tendencies | Neutral | Neutral |
Bearish
|
Please enable JavaScript in your browser settings to use dynamic graphics.  To sell |
|
| To buy | Medium consensus |
| TO BUY | Number of analysts |
| 5 |
Last closing price |
| $93.25 |
Average target price |
| $126.75 | Average Spread / Target |
Please enable JavaScript in your browser settings to use dynamic graphics.
